From: FGFR-TKI resistance in cancer: current status and perspectives
TKI classification | TKI name | Involved mechanisms |
---|---|---|
Pan-FGFR inhibitors | LY2874455 | FGFR2-ACSL5 fusion |
Multi-kinase inhibitors | Ponatinib | PTEN |
Nintedanib | ABCB1 induced drug-efflux; Lysosomal sequestration | |
Selective FGFR inhibitors | AZD4547 | Gene fusion: JHDM1D-BRAF fusion; Alternative pathways activation: RAS-MAPK pathway, ErbB3/PI3K/AKT pathway, MET; Related molecular abnormalities: RASA1, PHLDA1, PTEN, STAT3; Other: EMT; Drugs-efflux |
BGJ398 | Alternative pathways activation: RAS-MAPK pathway, PI3K/AKT /GSK pathway, MET, ErbB2/3 pathway; Related molecular abnormalities: NRAS, DUSP6; Other: EMT | |
PD173074 | EGFR signaling pathway; PHLDA1; EMT; Lysosomal sequestration | |
AZ12908010 | MET |